Improving Biopsies using Magnetic Nanoparticles

使用磁性纳米颗粒改善活检

• 批准号: 6932195
• 负责人: EDWARD R FLYNN
• 金额: $ 20.48万
• 依托单位: SENIOR SCIENTIFIC
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-07-20 至 2007-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6932195
• 关键词: antitumor antibody; bioengineering /biomedical engineering; biomedical equipment development; biopsy; bone marrow; bone marrow neoplasms; clinical biomedical equipment; clinical research; diagnosis quality /standard; human subject; immunomagnetic separation; model design /development; nanotechnology; neoplasm /cancer diagnosis; phantom model; surface coating

DESCRIPTION (provided by applicant): In children with acute lymphomatic leukemia (ALL) and in myelodysplastic syndrome (MDS) with older patients it is extremely important to measure the minimal residual disease (MRD) to monitor the progress of chemotherapy at early stages. Such measurements determine the prognosis, efficacy, and levels of the treatment. The normal method for detection and monitoring is through bone marrow biopsies. Unfortunately, this method, which has not changed in 40 years, requires multiple biopsies to obtain sufficient samples and these must be made at periodic intervals to monitor the treatment. The efficiency and specificity of biopsies can be improved through the use of labeled magnetic nanoparticles and "smart" magnetic collection methods. These antibody-labeled magnetic nanoparticles attach to specific cancer cells in large numbers and the cells are then collected magnetically. This magnetic biopsy technique samples more serum volume requiring fewer biopsies due to the increased efficiency and specificity for particular cell types. The method may also be used for sampling metastatic lesions and may be extended to solid tumors. Following these procedures, magnetic nanoparticles coated with anti-cancer agents may be magnetically concentrated, resulting in direct therapeutic intervention at the cancer site.

描述（由申请人提供）： 在儿童急性淋巴细胞白血病（ALL）和骨髓增生异常综合征（MDS）的老年患者中，在早期阶段测量微小残留病（MRD）以监测化疗的进展是极其重要的。这些测量确定治疗的预后、疗效和水平。检测和监测的常规方法是通过骨髓活检。不幸的是，这种40年来没有改变的方法需要多次活检才能获得足够的样本，并且必须定期进行活检以监测治疗。活检的效率和特异性可以通过使用标记的磁性纳米颗粒和“智能”磁性收集方法来提高。这些抗体标记的磁性纳米颗粒大量附着在特定的癌细胞上，然后通过磁性收集细胞。这种磁性活检技术由于提高了效率和对特定细胞类型的特异性，因此需要更少的活检来采集更多的血清体积。该方法也可用于转移性病变的取样，并可扩展到实体瘤。在这些程序之后，涂覆有抗癌剂的磁性纳米颗粒可以被磁性浓缩，从而在癌症部位进行直接治疗干预。